Finance

Lists
Why is ATHE down 4,01%?
Dive Deeper
ATHE:NASDAQ
Alterity Therapeutics Ltd
3,35 USD
-4,01%
(-0,14) 1D
2-окт., 10:11:24 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATHE...
Open
3,39 USD
High
3,42 USD
Low
3,33 USD
Mkt. cap
62,61 млн
Avg. vol.
17,59 миң
Volume
20,23 миң
52-wk high
5,89 USD
52-wk low
2,66 USD
EPS
-0,92 USD
Beta
0,29
Shares outstanding
19,10 млн
No. of employees
11
Open
3,39 USD
High
3,42 USD
Low
3,33 USD
Mkt. cap
62,61 млн
Avg. vol.
17,59 миң
Volume
20,23 миң
52-wk high
5,89 USD
52-wk low
2,66 USD
EPS
-0,92 USD
Beta
0,29
Shares outstanding
19,10 млн
No. of employees
11
News stories
From web sources and news partners
About Alterity Therapeutics Ltd
CEO-
Employees11
Founded1997
HeadquartersМельбурн, Виктория, Австралия
Sector-
Websitealteritytherapeutics.com
Analyst ratings
Based on 3 analysts giving stock ratings to ATHE in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ATHE in the last 3 months.
Highest
Current 3,35 USD
16,00 USD (+377,61%)
Average
12,67 USD (+278,21%)
Lowest
10,00 USD (+198,51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Flaten
Lake Street
Buy
Maintained
10,00 USD
+198,5%
09/28/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
16,00 USD
+377,6%
08/28/2026
Adam Vogel
Craig-Hallum
Buy
Initiated
12,00 USD
+258,2%
08/11/2026
Caroline Palomeque
Ladenburg Thalmann & Co.
Buy
Initiated
10,00 USD
+198,5%
06/16/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Initiated
10,00 USD
+198,5%
06/16/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
12,00 USD
+258,2%
06/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,40 млн
1,40 млн
403,29 миң
403,29 миң
Cost of goods sold
49,43 миң
49,43 миң
81,96 миң
81,96 миң
Cost of revenue
49,43 миң
49,43 миң
81,96 миң
81,96 миң
Research and development expenses
3,92 млн
3,92 млн
4,89 млн
4,89 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,56 млн
2,56 млн
2,71 млн
2,71 млн
Operating expense
6,57 млн
6,57 млн
7,65 млн
7,65 млн
Total operating expenses
6,62 млн
6,62 млн
7,73 млн
7,73 млн
Operating income
-5,22 млн
-5,22 млн
-7,32 млн
-7,32 млн
Other non operating income
-
-
-
-
EBT including unusual items
-4,78 млн
-4,78 млн
-6,87 млн
-6,87 млн
EBT excluding unusual items
-4,78 млн
-4,78 млн
-6,87 млн
-6,87 млн
Income tax expense
30,78 миң
30,78 миң
25,97 миң
25,97 миң
Effective tax rate
-0,64%
-0,64%
-0,38%
-0,38%
Other operating expenses
95,67 миң
95,67 миң
46,26 миң
46,26 миң
Net income
-4,81 млн
-4,81 млн
-6,89 млн
-6,89 млн
Net profit margin
-343,00%
-343,00%
-1 709,06%
-1 709,06%
Earnings per share
-
-
-
-
Interest and investment income
454,88 миң
454,88 миң
403,45 миң
403,45 миң
Interest expense
-
-
-
-
Net interest expenses
454,88 миң
454,88 миң
403,45 миң
403,45 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,22 млн
-5,22 млн
-7,32 млн
-7,32 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору